Tessera Therapeutics Revenue and Competitors
Claim your profile
Estimated Revenue & Valuation
- Tessera Therapeutics's estimated annual revenue is currently $45.4M per year.
- Tessera Therapeutics's estimated revenue per employee is $142,367
- Tessera Therapeutics's total funding is $431.8M.
- Tessera Therapeutics's current valuation is $1.7B. (April 2022)
Employee Data
- Tessera Therapeutics has 319 Employees.
- Tessera Therapeutics grew their employee count by 50% last year.
Tessera Therapeutics Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.2M | 1 | -99% | N/A | N/A |
#2 | $3.1M | 20 | 233% | N/A | N/A |
#3 | $21.5M | 125 | 18% | $351M | N/A |
#4 | $18M | 116 | 5% | $312.8M | N/A |
#5 | $235M | 269 | -43% | $340.9M | N/A |
#6 | $2.2M | 34 | 17% | N/A | N/A |
#7 | $6M | 40 | -9% | $176.5M | N/A |
#8 | $1.8M | 28 | 367% | N/A | N/A |
#9 | $109.4M | 706 | 14% | N/A | N/A |
#10 | $6.2M | 40 | 233% | N/A | N/A |
What Is Tessera Therapeutics?
Our mission is to cure disease by writing the code of life
keywords:N/A$431.8M
Total Funding
319
Number of Employees
$45.4M
Revenue (est)
50%
Employee Growth %
$1.7B
Valuation
N/A
Accelerator
Tessera Therapeutics News
2022-04-17 - Tessera Therapeutics Raises Over $300M in Series C Financing
Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding.
2022-04-17 - Tessera Therapeutics stacks up more than $300M in series C funds ...
Tessera Therapeutics, founded and created by life sciences VC staple Flagship Pioneering, is building a war chest with a fresh $300 million...
2022-04-17 - Tessera Therapeutics Announces Over $300M Series C Financing ...
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $108.3M | 321 | 4% | N/A |
#2 | $130.4M | 323 | 2% | N/A |
#3 | $47.3M | 327 | 27% | $520M |
#4 | $73.6M | 327 | N/A | N/A |
#5 | $79.9M | 332 | 25% | $382M |